The purpose of this observational study is to describe the safety and effectiveness of deucravacitinib in participants in Korea that have been diagnosed with moderate-to-severe plaque psoriasis.

Inclusion Criteria:

• Adult participants ≥19 years of age
• Diagnosis of moderate-to-severe plaque psoriasis
• Candidate for phototherapy or systemic therapy
• Will begin deucravacitinib according to approved product label

Exclusion Criteria:

• Participants prescribed deucravacitinib for therapeutic indications not approved in Korea
• Participants for whom deucravacitinib is contraindicated as clarified in Korean prescribing information by ministry of food and drug safety (MFDS)

The study population will include adult patients in Korea who have been diagnosed with moderate-to-severe plaque psoriasis and have been prescribed treatment with deucravacitinib according to the approved product label.